Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.61 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25590302 | 0.88 | PKM (0.59) | CREBBPPRKCIHSD17B1PKMPOLB | |
| SCHEMBL13986277 | 0.85 | PRKCI (0.50) | CREBBPPRKCIHSD17B1PKMPOLB | |
| SCHEMBL28220193 | 0.85 | PRKCI (0.50) | CREBBPPRKCIPKMPOLBRAB9A | |
| SCHEMBL4820728 | 0.85 | PRKCI (0.50) | CREBBPPRKCIPKMPOLBRAB9A | |
| SCHEMBL13654664 | 0.84 | PRKCI (0.50) | CREBBPPRKCIHSD17B1PKMPOLB | |
| SCHEMBL13654745 | 0.83 | PRKCI (0.57) | CREBBPPRKCIPKMHSD17B10MAPT | |
| SCHEMBL3131960 | 0.83 | GAA (0.61) | POLBRAB9ANPC1SMN1; SMN2USP2 | |
| SCHEMBL30269683 | 0.83 | GAA (0.61) | POLBRAB9ANPC1SMN1; SMN2USP2 | |
| SCHEMBL3517633 | 0.83 | KDM4E (0.47) | CREBBPRAB9ANPC1SMN1; SMN2USP2 | |
| SCHEMBL3279437 | 0.83 | PKM (0.57) | CREBBPHSD17B1PKMPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| EP-1991531-A1 | CINNOLINE AND QUINOXALINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1989195-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-12-13 | — | — | US | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100880-A1 | CINNOLINE AND QUINAZOLINE DERIVATES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | CREBBP 1056/4885PRKCI 671/4885HSD17B1 41/4885 |
| US-20070287707-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | CREBBP 1243/4885PRKCI 772/4885HSD17B1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.